Emergency oncology admissions during COVID-19 pandemic: a major institution experience from Saudi Arabia

Authors

  • O. Elemam Oncology Center, King Abdullah Medical City, Makkah 24246, Saudi Arabia
  • E. Tashkandi College of Medicine, Umm AlQura University, Makkah 24246, Saudi Arabia
  • S. Abdelkhalek Radiotherapy Department, Mansoura University, Mansoura 35516, Egypt
  • I. Shalaby Radiology Department, King Abdullah Medical City, Makkah 24246, Saudi Arabia
  • R. Baraka Diagnostic Medicine Center, Colorado State University, Fort Collins 80523, USA

DOI:

https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-1.15964

Keywords:

anticancer treatment, COVID-19, oncology admissions

Abstract

Background: The WHO has declared the coronavirus disease 2019 (COVID-19) pandemic in March 2020. Cancer patients are considered a highly susceptible group. The effect of this pandemic on cancer mortality is still unknown. Aim: Our aim is to know whether or not we need to postpone cancer treatment during viral pandemics in the future. Materials and Methods: A retrospective observational study from March 1, 2020 to June 1, 2020, included cancer patients on active treatment, who have been admitted to our oncology center through the emergency unit, and patients who received oncology treatment in the outpatient treatment unit. COVID-19 positive cases were identified based on polymerase chain reaction testing of nasopharyngeal swab. Results: A total of 1300 patients was included in the study, 1096 patients attended the outpatient clinics, 204 patients were admitted to our oncology floor for emergency care. The cancer diagnosis was mainly breast cancer, followed by colon cancer. The main cause of emergency room visit was mainly fever followed by pain. Admission diagnosis was mainly disease progression followed by symptom control, COVID-19 infection, and febrile neutropenia. 1288 cycles of anticancer therapy were provided to 513 patients in the outpatient treatment unit. Three out of the nineteen patients who had a confirmed COVID-19 infection (16%) died not only due to infection, but also disease progression. Conclusion: Cancer treatment is not a risk factor for COVID-19 infection or its complications. Cancer treatment should not be interrupted during viral pandemics and every effort should be made to give cancer patients the standard of care.

References

Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020; 323: 1775–6.

Burki TK. Cancer guidelines during the COVID-19 pandemic. Lancet Oncol 2020; 21: 629–30.

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.

Zhang C, Wu Z, Li JW, et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents 2020; 55: 105954.

Covid19.moh.gov.sa. COVID 19 Dashboard: Saudi Arabia.; c2020, Available from: https://covid19.moh.gov.sa/

Datasource.kapsarc.org.Saudi Arabia Coronavirus Disease Situation Demographics.; c2020, Available from: https://datasource.kapsarc.org/ explore/dataset/saudi-arabia-coronavirus-disease-covid-19-situation-demographics/

Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020; 31: 894–901.

Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020; 383: 120–8.

Ali J, Sajjad K, Farooqi AR, et al. COVID-19-positive cancer patients undergoing active anticancer treatment: An analysis of clinical features and outcomes, Hematology/Oncology and Stem Cell Therapy, 2020, https://doi.org/10.1016/j.hemonc.2020.12.001.

Jazieh A, Alenazi T, Alhejazi A, et al. Outcome of oncology patients infected with coronavirus. JCO Global Oncology 2020; 6: 471–5.

Warner J, Rubinstein S, Grivas P, et al. Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium. J Clin Oncol 2020; 38: LBA110.

Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak. Cancer Discov 2020; 10: 783–91.

Mehta V, Goel S, Kabarriti R, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov 2020; 10: 935–41.

Horn L, Whisenant J, Torri V, et al. Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival. J Clin Oncol 2020; 38: LBA111.

Lee L, Cazier J, Starkey T, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 2020; 395: 1919–26.

Robilotti EV, Babady NE, Mead PA, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med 2020; 26: 1218–23.

Downloads

Published

26.05.2023

How to Cite

Elemam, O., Tashkandi, E., Abdelkhalek, S., Shalaby, I., & Baraka, R. (2023). Emergency oncology admissions during COVID-19 pandemic: a major institution experience from Saudi Arabia. Experimental Oncology, 43(1), 31–35. https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-1.15964

Issue

Section

Original contributions